TuHURA Biosciences
HURA
2 hedge funds and large institutions have $89K invested in TuHURA Biosciences in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
75% less funds holding
Funds holding: 8 → 2 (-6)
77% less capital invested
Capital invested by funds: $391K → $89K (-$302K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$243K |
| 2 |
Barclays
London,
United Kingdom
|
-$35K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 4 |
Jane Street
New York
|
-$6K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$6K |
HURA Hedge Fund Activity: Q2 2019 in Review
2 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q2 2019, worth a combined $89K — down 77% from $391K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HURA and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, adding an estimated $146K. The largest seller was Sabby Management, exiting entirely with an estimated $243K sold.
- 2 institutional investors held TuHURA Biosciences (HURA) as of Q2 2019, down from 8 in Q1 2019.
- Funds reported $89K of TuHURA Biosciences stock for Q2 2019, down 77% quarter-over-quarter.
- 0 funds opened new TuHURA Biosciences positions in Q2 2019 and 6 closed out, a net change of -6 holders.
- The largest TuHURA Biosciences buyer in Q2 2019 was Virtu Financial, an estimated $146K added.
- The largest TuHURA Biosciences seller in Q2 2019 was Sabby Management, an estimated $243K sold.
Based on aggregated 13F filings for Q2 2019.